Financial Snapshot

Revenue
$105.3M
TTM
Gross Margin
Net Earnings
-$71.65M
TTM
Current Assets
Q3 2024
Current Liabilities
Q3 2024
Current Ratio
673.91%
Q3 2024
Total Assets
Q3 2024
Total Liabilities
Q3 2024
Book Value
$54.14M
Q3 2024
Cash
Q3 2024
P/E
-2.217
Nov 29, 2024 EST
Free Cash Flow
-$33.42M
TTM

Revenues

Revenues

Loading...

Revenue YoY Change

Loading...

Revenues

Concept 2023 2022 2021 2020 2019 2018 2017 2016
Revenue $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change

Expenses

Cost Of Revenues

Loading...

Gross Profit

Loading...

Gross Profit Margin

Loading...

Gross Profit

Concept 2023 2022 2021 2020 2019 2018 2017 2016
Revenue $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Loading...

Research & Development

Loading...

Depreciation, Depletion & Amortization

Loading...

SGA Expense to Gross Profit Ratio

Loading...

R&D To Gross Profit Ratio

Loading...

DDA To Gross Profit Ratio

Loading...

Operating Expenses Total

Loading...

Operating Profits/Loss

Loading...

Operational Expenses

Concept 2023 2022 2021 2020 2019 2018 2017 2016
Selling, General & Admin $38.46M $45.81M $44.08M $48.33M $38.24M $43.75M $260.0K $80.00K
YoY Change -16.05% 3.92% -8.79% 26.39% -12.59% 16726.92% 225.0%
% of Gross Profit
Research & Development $135.3M $170.9M $170.3M $160.9M $143.4M $55.28M $891.0K $0.00
YoY Change -20.84% 0.38% 5.85% 12.17% 159.4% 6104.6%
% of Gross Profit
Depreciation & Amortization $1.607M $1.832M $1.740M $1.409M $917.0K $297.0K $0.00 $0.00
YoY Change -12.28% 5.29% 23.49% 53.65% 208.75%
% of Gross Profit
Operating Expenses $183.8M $218.6M $216.1M $234.0M $186.1M $149.0M $6.653M $80.00K
YoY Change -15.94% 1.14% -7.62% 25.69% 24.93% 2139.49% 8216.25%
Operating Profit -$183.8M -$218.6M -$216.1M -$234.0M -$186.1M -$149.0M -$6.653M
YoY Change -15.94% 1.14% -7.62% 25.69% 24.93% 2139.49%

Interest Expenses

Loading...

Interest Expenses To Operating Income %

Loading...

Other Expense/Income

Loading...

Interest & Other Expense/Income

Concept 2023 2022 2021 2020 2019 2018 2017 2016
Interest Expense $13.51M $13.88M $19.44M $12.67M $1.938M $12.00K -$120.0K $0.00
YoY Change -2.66% -28.6% 53.48% 553.56% 16050.0% -110.0%
% of Operating Profit
Other Income/Expense, Net $3.942M $1.512M $799.0K -$174.0K $5.832M $2.024M -$118.0K $0.00
YoY Change 160.71% 89.24% -559.2% -102.98% 188.14% -1815.25%

Income/Loss

Pretax Income

Loading...

Income Tax

Loading...

Net Profits/Loss

Loading...

Pretax Income YoY Change

Loading...

Income Tax Rate

Loading...

Net Profits/Loss YoY Change

Loading...

Basic EPS

Loading...

Net Income To Revenue Ratio

Loading...

Pretax & Net Income

Concept 2023 2022 2021 2020 2019 2018 2017 2016
Pretax Income -$179.8M -$229.4M -$234.0M -$243.4M -$180.3M -$116.9M $6.771M -$80.00K
YoY Change -21.61% -1.98% -3.85% 34.97% 54.21% -1826.78% -8563.75%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income 0.0%
Net Earnings -$179.8M -$229.4M -$234.0M -$243.4M -$180.3M -$147.0M -$6.771M -$80.00K
YoY Change -21.61% -1.98% -3.84% 34.97% 22.68% 2070.57% 8363.75%
Net Earnings / Revenue
Basic Earnings Per Share -$1.18 -$2.71 -$3.13 -$3.55 -$3.29
Diluted Earnings Per Share -$1.18 -$2.71 -$3.13 -$3.55 -$3.29 -$2.231M -$107.0K -$1.264K

Assets & Liabilities

Cash & Short-Term Investments

Loading...

Cash & Equivalents

Loading...

Cash To Operating Expenses Ratio

Loading...

Inventory

Loading...

Receivables

Loading...

Total Short-Term Assets

Loading...

Property, Plant And Equipment

Loading...

Long-Term Investments

Loading...

Total Long-Term Assets

Loading...

Total Assets

Loading...

Net Income To Total Assets Percentage

Loading...

Accounts Payable

Loading...

Short-Term Debt

Loading...

Long Term Debt Due

Loading...

Total Short-Term Liabilities

Loading...

Long-Term Debt

Loading...

Other Long-Term Liabilities

Loading...

Total Long-Term Liabilities

Loading...

Total Liabilities

Loading...

Short-Term To Long-Term Debt Ratio

Loading...

Short-Term Assets To Debt Ratio

Loading...

Long-Term Debt To Net Income Ratio

Loading...

Assets & Liabilities

Concept 2023 2022 2021 2020 2019 2018 2017 2016
Cash & Short-Term Investments $296.4M $255.7M $325.2M $512.6M $401.8M $228.7M $300.0K $100.0K
YoY Change 15.94% -21.38% -36.56% 27.58% 75.69% 76133.33% 200.0%
Cash & Equivalents $32.11M $112.0M $183.4M $486.1M $135.1M $105.2M $300.0K $100.0K
Short-Term Investments $264.3M $143.7M $141.8M $26.60M $266.7M $123.4M $0.00 $0.00
Other Short-Term Assets $10.09M $6.202M $6.562M $9.700M $7.500M $3.300M $100.0K $0.00
YoY Change 62.75% -5.49% -32.35% 29.33% 127.27% 3200.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $306.5M $261.9M $331.8M $522.3M $409.3M $232.0M $400.0K $100.0K
YoY Change 17.05% -21.07% -36.48% 27.61% 76.42% 57900.0% 300.0%
Property, Plant & Equipment $4.779M $9.890M $10.80M $16.10M $15.70M $3.200M $0.00 $0.00
YoY Change -51.68% -8.4% -32.94% 2.55% 390.63%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $618.0K $680.0K $1.080M $1.000M $1.600M $4.300M $0.00 $0.00
YoY Change -9.12% -37.04% 8.0% -37.5% -62.79%
Total Long-Term Assets $5.397M $10.57M $11.88M $17.10M $17.30M $7.400M $0.00 $0.00
YoY Change -48.94% -11.0% -30.54% -1.16% 133.78%
Total Assets $311.9M $272.5M $343.7M $539.4M $426.6M $239.4M $400.0K $100.0K
YoY Change
Accounts Payable $5.526M $1.459M $3.244M $7.500M $1.000M $2.200M $100.0K $0.00
YoY Change 278.75% -55.02% -56.75% 650.0% -54.55% 2100.0%
Accrued Expenses $34.46M $36.16M $36.62M $31.10M $36.00M $18.20M $1.200M $100.0K
YoY Change -4.7% -1.25% 17.73% -13.61% 97.8% 1416.67% 1100.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $11.61M $11.61M
YoY Change 0.0%
Total Short-Term Liabilities $51.60M $49.23M $39.86M $38.70M $36.90M $20.40M $1.300M $100.0K
YoY Change 4.81% 23.51% 2.99% 4.88% 80.88% 1469.23% 1200.0%
Long-Term Debt $197.4M $207.7M $179.1M $172.4M $28.50M $0.00 $6.000M $0.00
YoY Change -4.96% 15.96% 3.9% 504.91% -100.0%
Other Long-Term Liabilities $144.0K $3.446M $3.218M $7.700M $8.700M $700.0K $0.00 $0.00
YoY Change -95.82% 7.09% -58.21% -11.49% 1142.86%
Total Long-Term Liabilities $197.5M $211.1M $182.3M $180.1M $37.20M $700.0K $6.000M $0.00
YoY Change -6.44% 15.8% 1.24% 384.14% 5214.29% -88.33%
Total Liabilities $249.1M $260.4M $222.2M $218.7M $74.10M $21.10M $7.300M $200.0K
YoY Change -4.31% 17.18% 1.6% 195.14% 251.18% 189.04% 3550.0%

Ownership

Basic Shares Outstanding

Loading...

Diluted Shares Outstanding

Loading...

Preferred Stock

Loading...

Treasury Stock Shares

Loading...

Stock Issuance & Repurchase

Loading...

Ownership Data

Concept 2023 2022 2021 2020 2019 2018 2017 2016
Basic Shares Outstanding 152.6M shares 84.57M shares 74.84M shares 68.51M shares 54.74M shares
Diluted Shares Outstanding 152.6M shares 84.57M shares 74.84M shares 68.51M shares 54.74M shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Loading...

Book Value

Loading...

Free Cash Flow

Loading...

Free Cash Flow YoY

Loading...

Free Cash Flow Margin

Loading...

Dividends

Dividends

Loading...

Stock Price

Loading...
Market Cap: $158.83 Million

About Gossamer Bio, Inc.

Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company is headquartered in San Diego, California and currently employs 135 full-time employees. The company went IPO on 2019-02-08. The firm is focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH). Its product candidate Seralutinib, also known as GB002, is an investigational inhaled, small molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor, being evaluated in a Phase III clinical trial for the treatment of PAH. In contrast to the three classes of marketed vasodilatory therapies for PAH, its seralutinib has the potential to reverse pathological remodeling by addressing mechanisms that underlie PAH. Inhaled seralutinib, which is designed to act on both isoforms of the PDGFR, α and β, as well as the CSF1R and c-KIT pathways. In addition to PAH, seralutinib holds the potential as a therapeutic option for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Industry: Pharmaceutical Preparations Peers: Vericel Corp CHINOOK THERAPEUTICS, INC. Arcutis Biotherapeutics, Inc. Avid Bioservices, Inc. FIBROGEN INC Kymera Therapeutics, Inc. RHYTHM PHARMACEUTICALS, INC. Sana Biotechnology, Inc. Zentalis Pharmaceuticals, Inc.